News

Tipranavir is a non-peptidic protease inhibitor (PI) that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents. The committee’s positive recommendation is

The investigational vaccine, Gardasil is designed to prevent infection from four common quadrivalent human papillomavirus (HPV) types and related cervical cancer, cervical pre-cancers and genital warts. The trial

The National Cancer Institute (NCI) and Bionaut will also collaborate to identify new biomarkers in tumor cells that are affected by Bionaut’s lead cancer compounds. Bionaut’s compounds will

Under the arrangement Enanta has been granted a non-exclusive license to Chiron’s hepatitis C virus (HCV) technology to further enable the research and development of HCV therapeutics. Enanta

Under the agreement, Basin Industrial, a wholly-owned subsidiary of Hong Kong based Advance Pharmaceutical Co (APC), will fund the manufacturing and marketing of products in China, Hong Kong,

The “Centre of Excellence for External Drug Discovery” (CEEDD) will work in partnership with biotechnology companies, small and mid-sized pharmaceutical companies and academic institutions to deliver compounds with

The study is in metastatic colorectal cancer patients who have disease progression after receiving standard chemotherapeutic regimens and is the result of a collaboration between Pro-Pharmaceuticals and the

ZIO-101 is the first compound from a family of novel organic arsenics. Preclinical evidence suggests that because of the potential for much higher doses and pharmacokinetic differences between

The trial is an escalating, repeated dose study of this new investigational drug in chronic lymphocytic leukemia (CLL) patients who have failed or no longer respond to chemotherapy.